The Movement Disorder Journal and News

The Brutal Math of Parkinson’s Clinical Trials

26 min · 6. juni 2026
episode The Brutal Math of Parkinson’s Clinical Trials cover

Description

In this episode, we explore the costs of clinical trials for both the patients and the drug companies, the risks that can come along with them, and the difficult balance between hope and uncertainty that exists in every study. We'll take a closer look at what it takes to bring a new treatment from the laboratory to the clinic, why so many promising therapies fail, and how the people who participate in clinical trials play a vital role in advancing medical science.

Comments

0

Be the first to comment

Sign up now and become a member of the The Movement Disorder Journal and News community!

Get Started

1 month for 9 kr.

Then 99 kr. / month · Cancel anytime.

  • Podcasts kun på Podimo
  • 20 lydbogstimer pr. måned
  • Gratis podcasts

All episodes

6 episodes

episode Neuralight's Eye-Movement Software and the MDS-UPDRS artwork

Neuralight's Eye-Movement Software and the MDS-UPDRS

In this episode, we sit down with Dr. Eitan Raveh, VP of Clinical Partnerships at NeuraLight, to explore a technology that could reshape how Parkinson's disease is measured and tracked in clinical trials. For nearly four decades, the MDS-UPDRS has been the gold standard for evaluating Parkinson's progression, but a new study suggests that a simple eye-tracking test, administered on a tablet in about ten minutes, may be more sensitive at detecting disease progression than the scale neurologists have relied on for generations. Dr. Raveh walks us through NeuraLight's landmark longitudinal study, what the Amplitude of Saccadic Hypometria actually measures, and why two of the scientists who helped build the MDS-UPDRS are now co-authors on a paper showing it may have met its match. If you follow Parkinson's research, drug development, or the future of digital biomarkers in neurology, this is a conversation you won't want to miss.

18. juni 202632 min